CareLit · DOI-Nachweis · Pneumologie
Entrectinib in neurotrophic receptor tyrosine kinase fusion-positive (NTRK- fp) non-small cell lung cancer (NSCLC): integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001
DOI 10.1055/s-0039-3403355
Bibliografische Angaben
Nachweis in CareLit
Autor:innenL Paz-Ares, RC Doebel, AF Farago, S Liu, SP Chawla, D Tosi, CM Blakely, JC Krauss, D Sigal, L Bazhenova, T John, B Besse, J Wolf, T Seto, E Chow-Maneval, C Ye, B Simmons, GD Demetri
ZeitschriftPneumologie
AusgabeS 01 S 01/2020
Jahrgang / SeitenJg. 74
Kernaussage aus der Literatur
Abstract-Vorschau
Entrectinib in neurotrophic receptor tyrosine kinase fusion-positive (NTRK- fp) non-small cell lung cancer (NSCLC): integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001
Zitieren
Zitierempfehlung
L Paz-Ares, RC Doebel, AF Farago, S Liu, SP Chawla, D Tosi, CM Blakely, JC Krauss, D Sigal, L Bazhenova, T John, B Besse, J Wolf, T Seto, E Chow-Maneval, C Ye, B Simmons, GD Demetri (2020) Entrectinib in neurotrophic receptor tyrosine kinase fusion-positive (NTRK- fp) non-small cell lung cancer (NSCLC): integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. Pneumologie, 74 (S 01 S 01). https://doi.org/10.1055/s-0039-3403355
Mit CareLit weiterarbeiten